AI app aims to boost Pill-Taking in underserved youth with epilepsy

NCT ID NCT07445074

Recruiting now Disease control Sponsor: University of Central Florida Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a smartphone app called Medilepsy®, which uses artificial intelligence to personalize reminders, helps teens and young adults (ages 14-24) with epilepsy take their anti-seizure medicine more regularly. The study will enroll 200 underserved participants in Florida and compare the AI version of the app to a standard version. The goal is to improve medication adherence and readiness to transition to adult healthcare.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Disease epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPSY SEIZURE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Orlando Health Arnold Palmer Hospital
RECRUITING

Orlando, Florida, 32806, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Orlando Health Orlando Regional Medical Center
RECRUITING

Orlando, Florida, 32806, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact